Alx Oncology Holding Shows Rising Price Performance With Jump To 87 RS Rating
Alx Oncology Holding had its Relative Strength (RS) Rating upgraded from 79 to 87 Monday.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves.
Alx Oncology Holding has risen more than 5% past a 46.73 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed -59% earnings growth in the latest quarterly report, while sales growth came in at -100%.
Alx Oncology Holding holds the No. 140 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical and Dynavax Technologies are also among the group's highest-rated stocks.